Finnish man­u­fac­tur­er to in­vest $55M+ in new fa­cil­i­ty for AAV ther­a­pies

Finnish bio­phar­ma­ceu­ti­cal con­tract man­u­fac­tur­er Biov­ian Oy is in­vest­ing €50 mil­lion ($55.3 mil­lion) to ex­pand its man­u­fac­tur­ing pres­ence in Fin­land and take on large-scale vi­ral vec­tor de­vel­op­ment.

Biov­ian said Wednes­day the new fa­cil­i­ty in Turku will be around 69,000 square feet and will house equip­ment and oth­er tech to sup­port the de­vel­op­ment and man­u­fac­tur­ing of “ad­vanced ther­a­py med­i­c­i­nal prod­ucts, in­clud­ing AAV ther­a­pies” and mi­cro­bial pro­teins.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER